Ferring Pharmaceuticals

Latest news

• FDA Approves Adstiladrin (nadofaragene firadenovec-vncg) for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
  16 December 2022
• FDA Approves Rebyota (fecal microbiota, live-jslm) Microbiota-Based Live Biotherapeutic for the Prevention of Recurrence of Clostridioides Difficile Infection
  30 November 2022
• Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
  7 November 2022
• Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
  22 September 2022
• Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
  24 May 2022
• Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
  29 September 2021
• Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
  21 May 2021
• Ortikos (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S.
  29 July 2020
• Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-Based Therapy RBX2660
  6 May 2020
• Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
  4 February 2020

Drugs Associated with Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. manufactures, markets and/or distributes more than 16 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Discontinued Drugs